Minh N. Q. Huynh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Minh N. Q. Huynh has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Lucas Gallo
Department of Surgery, McMaster University, Hamilton, ON, Canada
4 shared publications - Matthew C. McRae
McMaster University
3 shared publications - Morgan Yuan
University of Toronto
3 shared publications - Oluwatobi R. Olaiya
McMaster University
3 shared publications Aneesh Karir
University of Manitoba, Department of Surgery, Division of Plastic and Reconstructive Surgery, 66 Chancellors Circle, Winnipeg, Manitoba, R3T 2N2, Canada
2 shared publicationsCameron F. Leveille
Division of Plastic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
2 shared publications
Latest Publications
- 26 March 2026
- Published by Elsevier in The Journal of Hand Surgery
- Vol. 51 (6) , 634-640
Are There Thermal Risks Associated With Dry Arthroscopy? A Simulated Comparison of Temperatures in Wet Versus Dry Wrist Arthroscopy
- 26 March 2026
- Published by Elsevier in The Journal of Hand Surgery
- Vol. 51 (6) , 634-640
Are There Thermal Risks Associated With Dry Arthroscopy? A Simulated Comparison of Temperatures in Wet Versus Dry Wrist Arthroscopy
- 25 July 2025
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 109, 34-36
Motivating factors for patients seeking rhytidectomies: An exploratory qualitative analysis
- 25 July 2025
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 109, 34-36
Motivating factors for patients seeking rhytidectomies: An exploratory qualitative analysis
- 17 April 2024
- Published by Elsevier in Journal of Hand and Microsurgery
- Vol. 16 (4) , 100062
A systematic review of patient outcomes for primary pediatric flexor tendon repairs
- 17 April 2024
- Published by Elsevier in Journal of Hand and Microsurgery
- Vol. 16 (4) , 100062
A systematic review of patient outcomes for primary pediatric flexor tendon repairs
- 6 March 2024
- Published by SAGE Publications in Facial Plastic Surgery & Aesthetic Medicine
- Vol. 26 (2) , 236-244
Outcomes in Facial Feminization Surgery: A Systematic Review
Objective: Review literature on facial feminization surgery (FFS) for the transgender population and identify whether heterogeneity in reported outcomes and outcome measures exists across studies, as measured by a lack of consensus, and number of outcomes and outcome measures used. Evidence Review: A search of MEDLINE and EMBASE (database inception to January 20, 2021) was performed to retrieve FFS studies. Primary outcomes included number of reported outcomes and outcome measures; secondary outcomes included clinimetric properties of outcome measures and study characteristics. Findings: In total, 15 articles were included. Sixty-nine outcomes and 12 outcome measures were identified. Of those outcome measures, zero were found to be valid, reliable, and responsive in patients who had undergone FFS. A variety of FFS interventions were studied, with the three most common interventions being: rhinoplasty ( n = 7, 46.7%), mandibuloplasty ( n = 7, 46.7%), and chondrolaryngoplasty ( n = 6, 40%). Conclusion and Relevance: Heterogeneity was evident in reported outcomes and outcome measures in FFS literature and there is currently no outcome measure commonly used for this patient population.
- 6 March 2024
- Published by SAGE Publications in Facial Plastic Surgery & Aesthetic Medicine
- Vol. 26 (2) , 236-244
Outcomes in Facial Feminization Surgery: A Systematic Review
Objective: Review literature on facial feminization surgery (FFS) for the transgender population and identify whether heterogeneity in reported outcomes and outcome measures exists across studies, as measured by a lack of consensus, and number of outcomes and outcome measures used. Evidence Review: A search of MEDLINE and EMBASE (database inception to January 20, 2021) was performed to retrieve FFS studies. Primary outcomes included number of reported outcomes and outcome measures; secondary outcomes included clinimetric properties of outcome measures and study characteristics. Findings: In total, 15 articles were included. Sixty-nine outcomes and 12 outcome measures were identified. Of those outcome measures, zero were found to be valid, reliable, and responsive in patients who had undergone FFS. A variety of FFS interventions were studied, with the three most common interventions being: rhinoplasty ( n = 7, 46.7%), mandibuloplasty ( n = 7, 46.7%), and chondrolaryngoplasty ( n = 6, 40%). Conclusion and Relevance: Heterogeneity was evident in reported outcomes and outcome measures in FFS literature and there is currently no outcome measure commonly used for this patient population.
- 22 November 2023
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 88, 439-442
Comparison of skin grafts versus local flaps for facial skin cancer from the patient perspective: A feasibility study
- 22 November 2023
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 88, 439-442
Comparison of skin grafts versus local flaps for facial skin cancer from the patient perspective: A feasibility study
- Open Access
- 21 September 2023
- Published by SAGE Publications in Plastic Surgery
- Vol. 33 (1) , 68-77
Immediate Versus Delayed Mobilization After Cubital Tunnel Release Surgery: A Systematic Review and Meta-analysis
Purpose: It is unknown whether early mobilization after cubital tunnel decompression improves functional outcomes without increasing complication risks. This systematic review aims to evaluate the effectiveness of early mobilization compared to delayed mobilization of the elbow after ulnar nerve decompression. Methods: Randomized controlled trials (RCTs) and observational studies comparing adults who received early mobilization or late mobilization were included. Embase, MEDLINE, CENTRAL, PEDro, clinicaltrials.gov, and the World Health Organization database were systematically searched from inception to January 2023. Results: Of the 2183 studies identified and screened, five studies (two RCT and three observational) totaling 224 patients (232 elbows) were included in this review. Evidence from two RCTs (100 patients) suggests that early mobilization may result in a large reduction in the amount of time needed to return to work (mean difference 40.1 days, 95% confidence interval [CI] 16-64 days earlier, I 2 = 85%, low-certainty evidence) and little to no difference in grip strength (0 kg, 95% CI = −0.17 to 0.17, I 2 = 0%, low-certainty evidence). There was little to no difference in adverse events or range of motion (low to very-low certainty evidence). Pooled results from the three observational studies showed similar findings (very low-certainty evidence). There were no studies that evaluated upper extremity related quality of life. Conclusion: Immobilizing patients for periods longer than 3 days appears to delay patient's return to work with no appreciable clinical benefit.
- 21 September 2023
- Published by SAGE Publications in Plastic Surgery
- Vol. 33 (1) , 68-77
Open AccessImmediate Versus Delayed Mobilization After Cubital Tunnel Release Surgery: A Systematic Review and Meta-analysis
Purpose: It is unknown whether early mobilization after cubital tunnel decompression improves functional outcomes without increasing complication risks. This systematic review aims to evaluate the effectiveness of early mobilization compared to delayed mobilization of the elbow after ulnar nerve decompression. Methods: Randomized controlled trials (RCTs) and observational studies comparing adults who received early mobilization or late mobilization were included. Embase, MEDLINE, CENTRAL, PEDro, clinicaltrials.gov, and the World Health Organization database were systematically searched from inception to January 2023. Results: Of the 2183 studies identified and screened, five studies (two RCT and three observational) totaling 224 patients (232 elbows) were included in this review. Evidence from two RCTs (100 patients) suggests that early mobilization may result in a large reduction in the amount of time needed to return to work (mean difference 40.1 days, 95% confidence interval [CI] 16-64 days earlier, I 2 = 85%, low-certainty evidence) and little to no difference in grip strength (0 kg, 95% CI = −0.17 to 0.17, I 2 = 0%, low-certainty evidence). There was little to no difference in adverse events or range of motion (low to very-low certainty evidence). Pooled results from the three observational studies showed similar findings (very low-certainty evidence). There were no studies that evaluated upper extremity related quality of life. Conclusion: Immobilizing patients for periods longer than 3 days appears to delay patient's return to work with no appreciable clinical benefit.
- 30 March 2023
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 152 (6) , 993e-1004e
The Effects of Tranexamic Acid in Breast Surgery: A Systematic Review and Meta-Analysis
Background: Tranexamic acid (TXA) is used in trauma and surgical settings. Its role in reducing postoperative blood loss in breast surgery remains unclear. The primary objective of this study was to determine the effect of TXA on postoperative blood loss in breast surgery. Methods: Searches of the PubMed, Ovid MEDLINE, Embase, CINAHL, and Cochrane Central Register of Controlled Trials databases were performed from inception to April 3, 2020. Inclusion criteria were any retrospective reviews, prospective cohort studies, and randomized controlled trials that administered TXA (topical or intravenously) in the context of breast surgery. Quality of studies were evaluated using the risk of bias in randomized trials tool and the risk of bias in nonrandomized studies of interventions tool. Data were pooled, and a meta-analysis was performed. Results: In total, seven studies were included, representing 1226 patients (TXA, 632 patients; control, 622 patients). TXA was administered as follows: topically (20 mL of 25 mg/mL TXA intraoperatively; n =258 patients), intravenously (1 to 3 g perioperatively; n = 743 patients), or both (1 to 3 g daily up to 5 days postoperatively; n = 253 patients). TXA administration reduced hematoma formation in breast surgery (risk ratio, 0.48; 95% CI, 0.32 to 0.73), with no effect on drain output (mean difference, −84.12 mL; 95% CI, −206.53 to 38.29 mL), seroma formation (risk ratio, 0.92; 95% CI, 0.60 to 1.40), or infection rates (risk ratio, 1.01; 95% CI, 0.46 to 2.21). No adverse effects were reported. Conclusion: The use of TXA in breast surgery is a safe and effective modality with low-level evidence that it reduces hematoma rates without affecting seroma rates, postoperative drain output, or infection rates.
- 30 March 2023
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 152 (6) , 993e-1004e
The Effects of Tranexamic Acid in Breast Surgery: A Systematic Review and Meta-Analysis
Background: Tranexamic acid (TXA) is used in trauma and surgical settings. Its role in reducing postoperative blood loss in breast surgery remains unclear. The primary objective of this study was to determine the effect of TXA on postoperative blood loss in breast surgery. Methods: Searches of the PubMed, Ovid MEDLINE, Embase, CINAHL, and Cochrane Central Register of Controlled Trials databases were performed from inception to April 3, 2020. Inclusion criteria were any retrospective reviews, prospective cohort studies, and randomized controlled trials that administered TXA (topical or intravenously) in the context of breast surgery. Quality of studies were evaluated using the risk of bias in randomized trials tool and the risk of bias in nonrandomized studies of interventions tool. Data were pooled, and a meta-analysis was performed. Results: In total, seven studies were included, representing 1226 patients (TXA, 632 patients; control, 622 patients). TXA was administered as follows: topically (20 mL of 25 mg/mL TXA intraoperatively; n =258 patients), intravenously (1 to 3 g perioperatively; n = 743 patients), or both (1 to 3 g daily up to 5 days postoperatively; n = 253 patients). TXA administration reduced hematoma formation in breast surgery (risk ratio, 0.48; 95% CI, 0.32 to 0.73), with no effect on drain output (mean difference, −84.12 mL; 95% CI, −206.53 to 38.29 mL), seroma formation (risk ratio, 0.92; 95% CI, 0.60 to 1.40), or infection rates (risk ratio, 1.01; 95% CI, 0.46 to 2.21). No adverse effects were reported. Conclusion: The use of TXA in breast surgery is a safe and effective modality with low-level evidence that it reduces hematoma rates without affecting seroma rates, postoperative drain output, or infection rates.
- Open Access
- 23 March 2023
- Published by SAGE Publications in HAND
- Vol. 19 (6) , 1002-1011
Opioid Consumption After Upper Extremity Surgery: A Systematic Review
There is currently an overprescription of opioids, which may result in abuse and diversion of narcotics. The aim of this systematic review was to investigate opioid prescription practices and consumption by patients after upper extremity surgery. This review was registered a priori on Open Science Framework (osf.io/6u5ny) and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A search strategy was performed using MEDLINE, Embase, PubMed, and Cochrane Central Register of Controlled Trials databases (from their inception to October 17, 2021). Prospective studies investigating opioid consumption of patients aged 18 years or older undergoing upper extremity surgeries were included. The Risk of Bias in Nonrandomized Studies of Interventions and Risk of Bias 2.0 tools were used for quality assessment. In total, 21 articles met the inclusion criteria, including 7 randomized controlled trials and 14 prospective cohort studies. This represented 4195 patients who underwent upper extremity surgery. Most patients took less than half of the prescribed opioids. The percentage of opioids consumed ranged from 11% to 77%. There was moderate to severe risk of bias among the included studies. This review demonstrated that there is routinely excessive opioid prescription relative to consumption after upper limb surgery. Additional randomized trials are warranted, particularly with standardized reporting of opioid consumption and assessment of patient-reported outcomes.
- 23 March 2023
- Published by SAGE Publications in HAND
- Vol. 19 (6) , 1002-1011
Open AccessOpioid Consumption After Upper Extremity Surgery: A Systematic Review
There is currently an overprescription of opioids, which may result in abuse and diversion of narcotics. The aim of this systematic review was to investigate opioid prescription practices and consumption by patients after upper extremity surgery. This review was registered a priori on Open Science Framework (osf.io/6u5ny) and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A search strategy was performed using MEDLINE, Embase, PubMed, and Cochrane Central Register of Controlled Trials databases (from their inception to October 17, 2021). Prospective studies investigating opioid consumption of patients aged 18 years or older undergoing upper extremity surgeries were included. The Risk of Bias in Nonrandomized Studies of Interventions and Risk of Bias 2.0 tools were used for quality assessment. In total, 21 articles met the inclusion criteria, including 7 randomized controlled trials and 14 prospective cohort studies. This represented 4195 patients who underwent upper extremity surgery. Most patients took less than half of the prescribed opioids. The percentage of opioids consumed ranged from 11% to 77%. There was moderate to severe risk of bias among the included studies. This review demonstrated that there is routinely excessive opioid prescription relative to consumption after upper limb surgery. Additional randomized trials are warranted, particularly with standardized reporting of opioid consumption and assessment of patient-reported outcomes.
- 21 March 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (6) , 489-493
A comparison of skin grafts versus local flaps for facial skin cancer from the patient perspective: protocol for a feasibility study
Brief This is a protocol to assess feasibility of conducting a prospective cohort study comparing local flaps versus skin grafts for surgical excision of skin cancer from the face. Introduction: Skin cancer is the most common malignancy worldwide and the face is one of the most common locations of occurrence. Surgical excision is the most popular treatment for small lesions of the face. Defects can be reconstructed using local flaps or skin grafts. There is a paucity of literature evaluating outcomes after skin cancer surgery from the patient’s perspective using valid measurement tools. The purpose of this study is to assess the feasibility of conducting a prospective observational cohort study. The primary outcomes include recruitment rates, eligibility rate, compliance of intervention and rate of completion of the primary outcome (FACE-Q scales) at 3 months. Secondary outcomes include examining patient characteristic and FACE-Q score differences between local flaps to skin grafts and adverse events. Methods and analysis: This study is a prospective cohort study consisting of an anticipated 30 patients aged ≥18 years. The study population will consist of a consecutive sample of non-melanoma facial skin cancer patients undergoing a skin graft or local flap. Patients will be followed and evaluated with the FACE-Q questionnaire at 2 weeks, 3 months, 6 months and 1 year post-operation. The following criteria will determine success: patients who meet eligibility criteria >70%; recruitment rate >70%; compliance with intervention >90%; rate of completion of full-scale prospective study primary outcome (FACE-Q at 3 months) >80%; retention rate at 6-month follow-up visit >70%. Discussion: The findings of this study will be used to guide the sample size calculation for a future, large-scale prospective study. Trial registration: ClinicalTrials.gov (NCT04842279).
- 21 March 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (6) , 489-493
A comparison of skin grafts versus local flaps for facial skin cancer from the patient perspective: protocol for a feasibility study
Brief This is a protocol to assess feasibility of conducting a prospective cohort study comparing local flaps versus skin grafts for surgical excision of skin cancer from the face. Introduction: Skin cancer is the most common malignancy worldwide and the face is one of the most common locations of occurrence. Surgical excision is the most popular treatment for small lesions of the face. Defects can be reconstructed using local flaps or skin grafts. There is a paucity of literature evaluating outcomes after skin cancer surgery from the patient’s perspective using valid measurement tools. The purpose of this study is to assess the feasibility of conducting a prospective observational cohort study. The primary outcomes include recruitment rates, eligibility rate, compliance of intervention and rate of completion of the primary outcome (FACE-Q scales) at 3 months. Secondary outcomes include examining patient characteristic and FACE-Q score differences between local flaps to skin grafts and adverse events. Methods and analysis: This study is a prospective cohort study consisting of an anticipated 30 patients aged ≥18 years. The study population will consist of a consecutive sample of non-melanoma facial skin cancer patients undergoing a skin graft or local flap. Patients will be followed and evaluated with the FACE-Q questionnaire at 2 weeks, 3 months, 6 months and 1 year post-operation. The following criteria will determine success: patients who meet eligibility criteria >70%; recruitment rate >70%; compliance with intervention >90%; rate of completion of full-scale prospective study primary outcome (FACE-Q at 3 months) >80%; retention rate at 6-month follow-up visit >70%. Discussion: The findings of this study will be used to guide the sample size calculation for a future, large-scale prospective study. Trial registration: ClinicalTrials.gov (NCT04842279).